President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

Several companies, including Oracle and Microsoft, are expected to sign pledges to work on the Trump administration ...

The GOP megabill now under Senate consideration threatens healthcare insurance for more than 1 million seniors who rely on Medicare.

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

In letters posted on Truth Social, Trump demanded that drugmakers offer their medications at the same prices paid abroad.

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...